Intrexon Corp (XON) : Third Security scooped up 99,096 additional shares in Intrexon Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 62,246,397 shares of Intrexon Corp which is valued at $1,515.7 Million.Intrexon Corp makes up approximately 77.88% of Third Security’s portfolio.
Other Hedge Funds, Including , Atlantic Trust Group boosted its stake in XON in the latest quarter, The investment management firm added 1,480 additional shares and now holds a total of 13,687 shares of Intrexon Corp which is valued at $333,278.Manufacturers Life Insurance Company The boosted its stake in XON in the latest quarter, The investment management firm added 260 additional shares and now holds a total of 3,242 shares of Intrexon Corp which is valued at $78,943.Profund Advisors reduced its stake in XON by selling 6,879 shares or 19.59% in the most recent quarter. The Hedge Fund company now holds 28,239 shares of XON which is valued at $740,144. Intrexon Corp makes up approx 0.04% of Profund Advisors’s portfolio.Stephens Inc Ar boosted its stake in XON in the latest quarter, The investment management firm added 26,959 additional shares and now holds a total of 47,109 shares of Intrexon Corp which is valued at $1.2 Million. Intrexon Corp makes up approx 0.06% of Stephens Inc Ar’s portfolio.Swiss National Bank boosted its stake in XON in the latest quarter, The investment management firm added 15,900 additional shares and now holds a total of 78,400 shares of Intrexon Corp which is valued at $2.1 Million.
Intrexon Corp opened for trading at $24.63 and hit $25.95 on the upside on Monday, eventually ending the session at $25.55, with a gain of 4.93% or 1.2 points. The heightened volatility saw the trading volume jump to 21,26,366 shares. Company has a market cap of $3,019 M.
On the company’s financial health, Intrexon Corp reported $-0.55 EPS for the quarter, missing the analyst consensus estimate by $ -0.39 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.16. The company had revenue of $43.40 million for the quarter, compared to analysts expectations of $46.25 million. The company’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $+0.25 EPS.
Many Wall Street Analysts have commented on Intrexon Corp. Intrexon Corp was Initiated by JMP Securities to “Mkt Outperform” on May 3, 2016. Shares were Reiterated by Stifel on Mar 1, 2016 to “Buy” and Lowered the Price Target to $ 57 from a previous price target of $69 .Company shares were Reiterated by Mizuho on Mar 1, 2016 to “Neutral”, Firm has raised the Price Target to $ 29 from a previous price target of $28 .
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.